Tumori Journal最新文献

{"title":"Get up, stand up: Alongside adolescents and young adults with cancer for their right to be forgotten","authors":"P. Quarello, A. Toss, M. Mascarin, G. Banna, M. Canesi, G. Milano, L. Incorvaia, M. Lambertini, M. Terenziani, C. Clerici, G. Vigevani, G. Beretta, A. Prete, S. Cinieri, F. Peccatori, A. Ferrari","doi":"10.1177/03008916221101652","DOIUrl":"https://doi.org/10.1177/03008916221101652","url":null,"abstract":"Adolescent and young adult cancer survivors may experience various forms of social difficulties years or even decades after completing their cancer treatments. This article will hopefully help the Italian national project dedicated to adolescents and young adults with cancer promoting political and legal solutions to stop discrimination and supporting the right to be forgotten.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"25 1","pages":"402 - 406"},"PeriodicalIF":0.0,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88326456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic pheochromocytomas and paragangliomas: where are we?","authors":"N. Prinzi, F. Corti, M. Torchio, M. Niger, M. Antista, F. Pagani, T. Beninato, I. Pulice, R. Rossi, J. Coppa, T. Cascella, L. Giacomelli, M. Di Bartolomeo, M. Milione, F. de Braud, S. Pusceddu","doi":"10.1177/03008916221078621","DOIUrl":"https://doi.org/10.1177/03008916221078621","url":null,"abstract":"Pheochromocytomas and paragangliomas (PPGLs) can metastasize in approximately 15–20% of cases. This review discusses the available evidence on the biology and treatment of metastatic PPGLs. Chemotherapy is the first-line treatment option for this evolving and symptomatic disease. In patients with high MIBG uptake and positive PETGa-68, radiometabolic treatment may be considered. The efficacy of sunitinib has been shown in observational studies, and pembrolizumab has been evaluated in phase II clinical studies, while other agents investigated in this setting are anti-angiogenic drugs cabozantinib, dovitinib, axitinib and lenvatinib. As these agents' efficacy and safety data, alone or in combination, are scant and based on few treated patients, enrollment in clinical trials is mandatory. Future therapeutic options may be represented by DNA repair system inhibitors (such as olaparib), HIF2 inhibitors and immunotherapy.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"3 2 1","pages":"526 - 540"},"PeriodicalIF":0.0,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88355468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 immunization in people with cancer—Is it safe and efficient? What do we know?","authors":"Diana-Elena Lazăr, A. Munteanu","doi":"10.1177/03008916221090544","DOIUrl":"https://doi.org/10.1177/03008916221090544","url":null,"abstract":"Prior to the COVID-19 pandemic, vaccination of people with cancer or a recent history of cancer was advisable under specific conditions, depending on the type of vaccine (inactivated or live attenuated virus or bacterium), type of cancer, and whether they had undergone treatment for cancer. Some malignancies, especially hematological malignancies, and cancer treatments such as chemotherapy, radiotherapy, and splenectomy negatively impact the immune response. The clinical trials of currently used vaccines against COVID-19 did not include people with active cancer; thus, there is an important gap in the knowledge of safety and efficiency data for COVID-19 immunization in this population. However, considering the risk of mortality and morbidity due to possible infection with SARS-CoV-2, medical experts recommend immunization on an individual basis. As the worldwide prevalence of malignancies is high, reliable information on COVID-19 vaccination is expected to be revealed in future clinical trials. In this review, we examine the key aspects of cancer that may be affected by COVID-19 and summarize the current literature on COVID-19 immunization.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"25 1","pages":"420 - 430"},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80046724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Squamous cell histological transformation in a lung adenocarcinoma patient (hyper) progressing upon immunotherapy","authors":"A. Mariniello, L. Righi, A. Morrone, S. Carnio, P. Bironzo","doi":"10.1177/03008916221080487","DOIUrl":"https://doi.org/10.1177/03008916221080487","url":null,"abstract":"Introduction: In non-small cell lung cancer (NSCLC) histologic transformation upon immune checkpoint inhibitors (ICI) is rare. Case presentation: We described the case of a patient with early-stage lung adenocarcinoma who relapsed after surgery. At the time of relapse, he received chemo-radiotherapy, followed by consolidation immunotherapy. After 3 cycles the patient experienced disease hyperprogression for onset of a new lung mass, which resulted in squamous cell carcinoma. The preservation of an atypical mutation in the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene in both the primary adenocarcinoma and the new squamous carcinoma suggests histological transformation, likely ICI-related. Discussion: We reviewed similar cases in literature, highlighting common patterns and substantial differences. For a deeper insight into inherent biological mechanisms, re-biopsy in case of atypical ICI response should be encouraged.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"14 1","pages":"NP15 - NP19"},"PeriodicalIF":0.0,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75531287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life and financial toxicity after (chemo)radiation therapy in head and neck cancer: are there any sex- or gender-related differences?","authors":"F. De Felice, L. Locati, S. Ronchi, J. Thariat, E. Orlandi","doi":"10.1177/03008916221078885","DOIUrl":"https://doi.org/10.1177/03008916221078885","url":null,"abstract":"The purpose of this article is to discuss the published evidence related to quality of life (QoL) and financial toxicity (FT) differences between female and male head and neck cancer patients treated with (chemo)radiotherapy. There is a need of promoting methods for assessing QoL difference between female and male patients in order to set up early rehabilitation, psychosocial care, and lifestyle interventions, as well as setting up specific interventions for minimizing financial stress.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"50 1","pages":"522 - 525"},"PeriodicalIF":0.0,"publicationDate":"2022-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76277072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paraneoplastic neurological syndromes in patients affected by SCLC: a case series","authors":"C. Zanella, A. G. Leone, L. Zambelli, A. Bottiglieri, L. Canziani, M. Brambilla, G. Lo Russo, M. Platania, F. de Braud, M. Occhipinti","doi":"10.1177/03008916221079663","DOIUrl":"https://doi.org/10.1177/03008916221079663","url":null,"abstract":"Paraneoplastic syndromes occur in about 0.1% of patients affected by neoplastic diseases. In some types of tumors, such as Small Cell Lung Cancer (SCLC), Thymoma, and particular forms of Plasmacytoma, the association with Paraneoplastic Neurological Syndromes (PNS) is much more frequent. It seems that these syndromes are triggered by tumor production of factors normally expressed only by the individual's nervous system. The immune system stimulates an autoimmune response against these factors that induce neurological symptoms. Also, in light of the latest updates on the relationship between immunotherapy and PNS as well as of the introduction of first-line immunotherapy in SCLC, it seems that the use of immunotherapy in SCLC is associated with concomitant increase in autoimmune neurological syndromes. In this article, we report our experience at Istituto Nazionale Tumori of Milan with three patients affected by SCLC and PNS. Our experience seems to confirm that the oncological treatment scarcely impacts the paraneoplastic neurological deficits. Further research is needed to improve the treatment and recovery of patients affected by PNS.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"4 1","pages":"NP11 - NP14"},"PeriodicalIF":0.0,"publicationDate":"2022-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75406709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Playing cards designed by young cancer patients with the Youth Project in Milan","authors":"A. Ferrari, Matteo Silva, Alice Patriccioli, M. Chisari, C. Clerici, M. Massimino","doi":"10.1177/03008916221080189","DOIUrl":"https://doi.org/10.1177/03008916221080189","url":null,"abstract":"This short piece briefly describes a creative project undertaken by a group of adolescent and young adult cancer patients as part of our Youth Project (a scheme dedicated to young cancer patients with the dual aim of optimizing medical aspects of their care and promoting a holistic approach to their needs, including the organization of artistic activities). In this project, young cancer patients designed their personalized playing cards, with kings receiving chemo, queens wearing bandanas, jacks dressed as nurses, and jokers as doctors. The playing cards, with the patients’ own words, contain a little bit of these young cancer patients’ stories in them.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"12 1","pages":"189 - 190"},"PeriodicalIF":0.0,"publicationDate":"2022-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82881324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BGICC Conference Abstract Book 2022","authors":"","doi":"10.1177/03008916221078062","DOIUrl":"https://doi.org/10.1177/03008916221078062","url":null,"abstract":"","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"108 1","pages":"2 - 30"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85656126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AIOM abstracts","authors":"M. Firrincieli, L. Maiorana, A. Cappello, G. Lo Presti, A. Lucenti, C. Lancia, D. Di Noto, S. Cordio","doi":"10.1177/03008916211041664","DOIUrl":"https://doi.org/10.1177/03008916211041664","url":null,"abstract":"Background: In December 2020, thanks to the collaboration among the U.O.C. Oncologia, Roche Italia, and our Association, was set up a project for the domiciliation of antiblastic treatment titled “HER Home”, at the ASP 7 Ragusa in Sicily. The project involving patients with HER2 positive breast cancer concerns treatment at home with subcutaneous antiblastic therapy. Aims include the enhancement of patients' quality of life reducing the need for travel and visits to the hospital and making them more comfortable to receive the therapy. During the current pandemic situation, this means a greater safety for patients who are fragile subjects and may be more exposed to the risk of infection;and, also, the improvement in organizational efficiency. Materials and methods: Admission of patients takes place according to the evaluation of the Medical Oncologists who establish the schedule of treatments and prescribe the drug. The drug is prepared and dispensed by the hospital pharmacy. Our Association, already active for home palliative care, deals with the transport of the drug from the hospital pharmacy to the patients' home, where our Doctor, after a clinical evaluation of the patient, administers the drug. The project foresees the participation of 20 women and about 240 administrations. Quality of life will be assessed at baseline and every 4 administrations, using patient's self-reported outcome measures (PROMs). Results: To date, have been assisted 4 patients and carried out 13 administrations. No adverse events have occurred and no organizational criticalities were recorded. All administrations were performed safely, within the foreseen times and methods. Conclusions: The project has allowed the patients involved to have more free time since there are no needs for transfers and waiting times in the Day Hospital and so allowing them don't change the course of their daily routine;we, also, expect a measurable improvement in the quality of life. For the regional health system, this project achieved a simplification of the pathways and a reduction in the crowding of the Hospital, both essential during the COVID-19 pandemic. From the economic point of view, the project reduced costs and resources applied for about 30% less. The potential shown by this preliminary project could be fully realized in the evaluation of the possibility of home administration of other antiblastic therapies favoring above all the patients who lead a very active working and family life.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"1 1","pages":"1 - 188"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73217685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hippocampal Dosimetric Evaluation in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Intensity Modulated Radiotherapy","authors":"Moustafa Al Daly, N. Makady","doi":"10.1177/03008916211012339","DOIUrl":"https://doi.org/10.1177/03008916211012339","url":null,"abstract":"Introduction: Treatment of locally advanced nasopharyngeal (Npx) cancer usually requires the inclusion of the sphenoid body or higher in intermediate risk CTV dose regions. This makes the avoidance of intracranial OAR such as temporal lobes, optic apparatus and cochlea challenging. There are different accumulating data confirming the impact of hippocampus (HC) irradiation on neurocognitive functions after whole brain radiotherapy & Npx cases were specifically addressed in several publications. The specified dose constrain in RTOG 0933 was Dmax <9 Gy. Our aim is to retrospectively evaluate the doses delivered to the HC in patients with locally advanced Npx carcinoma. Methods: Our study included twelve patients with locally advanced nasopharyngeal carcinoma (Stage III-IVA) previously treated at NEMROCK by either IMRT or VMAT. The HC was retrospectively delineated without being accounted for in the inverse treatment planning. Bilateral HC were delineated as a single OAR, and a margin of 3 mm was added to create the HC zone. We evaluated the doses delivered to the hippocampus by conducting a dosiemtric analysis on the treatment plan already used. Results: DVH Analysis: The mean volumes (std) for PTV70 primary, PTV70 LN and PTV59.4 were 83.62 cm3 (±33.51), 119.5 cm3 (±122.66) and 1017.58 cm3 (±140.28) respectively. The mean HC volume (std) was 4.17 cm3 (±1.66). The mean HC Dmin, Dmean, Dmedian and Dmax were 6.57 Gy, 25.05 Gy, 24.18 Gy and 52.95 Gy respectively. The mean HC V5, V10, V20, V40, V50 and V60 were 92.83%, 78.95%, 55.91%, 20.37%, 9.9% and 3.38% respectively. There was no difference between IMRT and VMAT in terms of HC volumetric and dosimetric parameters. Conclusion: In locally advanced Npx carcinoma, HC is exposed to significant doses, particularly with T4 disease (intracranial extension). In view of the low radiation tolerance of HC and its close proximity to CTV54-60 Gy in Npx cases, HC contouring and avoidance should be considered.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"50 1","pages":"10 - 10"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74252031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}